Menu Search
Equities

SenzaGen AB

26S:BER

SenzaGen AB

Actions
  • Price (EUR)0.612
  • Today's Change0.008 / 1.32%
  • Shares traded--
  • 1 Year change+4.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 14:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

  • Revenue in SEK (TTM)--
  • Net income in SEK--
  • Incorporated2010
  • Employees33.00
  • Location
    SenzaGen ABMedicon VillageBuilding 401, Scheelevagen 2LUND 223 63SwedenSWE
  • Phone+46 462756200
  • Websitehttps://senzagen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.